The AI engine is offline (last seen Aug 12, 05:02 UTC). Scores are shown as of their timestamps; new theses and refreshes are queued and run the moment it returns.

Macro

Search catalysts, news stories, and pressures, or browse the trust-weighted news feed below.

Home tech energy finance healthcare defense industrial consumer communication utilities real estate raw materials
← back
healthcare · sector mood
2008
year mood -0.03 · -0.20 to +0.10 across 12 mo
Monthly mood
bearish −1 +1 bullish
-0.25 -0.12 0 +0.12 +0.25 Jan Feb +0.10 Mar Apr May Jun Jul Aug Sep Oct -0.20 Nov Dec
month values ▾
JanFebMarAprMayJunJulAugSepOctNovDec
-0.17+0.10+0.00+0.10+0.10+0.00+0.08+0.00-0.10-0.20-0.20-0.10

Post-Lehman panic; even defensives fall, biotech funding freezes

How this mood is scored ▾
Each day the model reads that day's news for the sector and asks, as someone who owns assets or makes their living in it: how am I feeling this month, and why? The month's mood is that running answer, tied to the specific events driving it (the story shown above). It leans on trusted, higher-impact reporting, and on the prior month when a month is quiet, so one loud headline can't swing it. The read updates daily through the month; once a month ends, its mood is locked. This year is read live from the news the pipeline actually collected (hover a bar for its story count). · last computed Jul 11, 2026
Top healthcare stories of 2008
Jan
Vytorin's ENHANCE trial shows no plaque benefit, jolting cholesterol-drug makers forbes.com →

On January 14, 2008, long-delayed results from the ENHANCE trial showed that Merck and Schering-Plough's cholesterol drug Vytorin lowered LDL far more than a generic statin yet failed to slow arterial plaque. Prescriptions for the roughly $5-billion-a-year franchise plunged and both companies' shares fell amid scrutiny over the nearly two-year delay in releasing the data.

Jul
Roche bids $43.7B to acquire Genentech cnbc.com →

Swiss pharmaceutical giant Roche offered $43.7 billion to buy out remaining shares of U.S. biotech leader Genentech, aiming to strengthen its oncology portfolio and drive cost synergies. The bid, below market expectations, triggered investor concern over financing, though Roche plans to use cash and debt. The move underscores Big Pharma's push to bolster pipelines amid generic competition and pricing pressures.